{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T20:09:52Z","timestamp":1793650192667,"version":"4.5.1"},"reference-count":32,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82302346"],"award-info":[{"award-number":["82302346"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["22371059"],"award-info":[{"award-number":["22371059"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82411540243"],"award-info":[{"award-number":["82411540243"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012226","name":"Fundamental Research Funds for the Central Universities","doi-asserted-by":"publisher","award":["HIT.OCEF.2022040"],"award-info":[{"award-number":["HIT.OCEF.2022040"]}],"id":[{"id":"10.13039\/501100012226","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012272","name":"Shenzhen Technology Development Program","doi-asserted-by":"publisher","award":["GJHZ20220913143010018"],"award-info":[{"award-number":["GJHZ20220913143010018"]}],"id":[{"id":"10.13039\/501100012272","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012272","name":"Shenzhen Technology Development Program","doi-asserted-by":"publisher","award":["JCYJ20210324132815037"],"award-info":[{"award-number":["JCYJ20210324132815037"]}],"id":[{"id":"10.13039\/501100012272","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012272","name":"Shenzhen Technology Development Program","doi-asserted-by":"publisher","award":["GXWD20220818171934001"],"award-info":[{"award-number":["GXWD20220818171934001"]}],"id":[{"id":"10.13039\/501100012272","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100021176","name":"Shandong Key Laboratory of Biochemical Analysis","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100021176","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010226","name":"Department of Education of Guangdong Province","doi-asserted-by":"publisher","award":["2022ZDZX2065"],"award-info":[{"award-number":["2022ZDZX2065"]}],"id":[{"id":"10.13039\/501100010226","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010226","name":"Department of Education of Guangdong Province","doi-asserted-by":"publisher","award":["2021KQNCX276"],"award-info":[{"award-number":["2021KQNCX276"]}],"id":[{"id":"10.13039\/501100010226","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010226","name":"Department of Education of Guangdong Province","doi-asserted-by":"publisher","award":["2023KTSCX225"],"award-info":[{"award-number":["2023KTSCX225"]}],"id":[{"id":"10.13039\/501100010226","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100016109","name":"Taishan Industry Leading Talents","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100016109","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100021171","name":"Basic and Applied Basic Research Foundation of Guangdong Province","doi-asserted-by":"publisher","award":["2022A1515220158"],"award-info":[{"award-number":["2022A1515220158"]}],"id":[{"id":"10.13039\/501100021171","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100021171","name":"Basic and Applied Basic Research Foundation of Guangdong Province","doi-asserted-by":"publisher","award":["2024A1515010898"],"award-info":[{"award-number":["2024A1515010898"]}],"id":[{"id":"10.13039\/501100021171","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Therapy"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1016\/j.ymthe.2025.12.002","type":"journal-article","created":{"date-parts":[[2025,12,4]],"date-time":"2025-12-04T16:34:41Z","timestamp":1764866081000},"page":"1435-1447","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["On-target\/off-tumor toxicities following infusion of low-affinity Nectin-4-specific CAR T cells"],"prefix":"10.1016","volume":"34","author":[{"given":"Liya","family":"Ma","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ming","family":"Wen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mengjiao","family":"Yao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaiwen","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ting","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fengyi","family":"Ren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dong","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Minying","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hao","family":"Deng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yonggui","family":"Hong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuaiqi","family":"Yuan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xudong","family":"Xia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heng","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhiqiang","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xingyi","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Baozhong","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-4638-5116","authenticated-orcid":false,"given":"Hongxing","family":"Jason-Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ymthe.2025.12.002_bib1","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1056\/NEJMoa1804980","article-title":"Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma","volume":"380","author":"Schuster","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ymthe.2025.12.002_bib2","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1056\/NEJMoa1707447","article-title":"Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma","volume":"377","author":"Neelapu","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ymthe.2025.12.002_bib3","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1016\/S0140-6736(20)31366-0","article-title":"Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study","volume":"396","author":"Abramson","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.ymthe.2025.12.002_bib4","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1016\/S0140-6736(21)00933-8","article-title":"Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b\/2 open-label study","volume":"398","author":"Berdeja","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.ymthe.2025.12.002_bib5","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1056\/NEJMoa2024850","article-title":"Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma","volume":"384","author":"Munshi","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ymthe.2025.12.002_bib6","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/S0140-6736(21)01222-8","article-title":"KTE-X19 for relapsed or refractory adult B-cell acute lymphoblastic leukaemia: phase 2 results of the single-arm, open-label, multicentre ZUMA-3 study","volume":"398","author":"Shah","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.ymthe.2025.12.002_bib7","doi-asserted-by":"crossref","first-page":"1595","DOI":"10.1158\/1078-0432.CCR-20-2448","article-title":"T-cell\u2013engaging Therapy for Solid Tumors","volume":"27","author":"de Miguel","year":"2021","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ymthe.2025.12.002_bib8","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-002723","article-title":"Adoptive cellular therapy in solid tumor malignancies: review of the literature and challenges ahead","volume":"9","author":"Kirtane","year":"2021","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.ymthe.2025.12.002_bib9","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1186\/s40164-023-00373-7","article-title":"Current advances and challenges in CAR T-Cell therapy for solid tumors: tumor-associated antigens and the tumor microenvironment","volume":"12","author":"Yan","year":"2023","journal-title":"Exp. Hematol. Oncol."},{"key":"10.1016\/j.ymthe.2025.12.002_bib10","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2021.108260","article-title":"CAR T cell therapy in solid tumors; with an extensive focus on obstacles and strategies to overcome the challenges","volume":"101","author":"Khorasani","year":"2021","journal-title":"Int. Immunopharmacol."},{"key":"10.1016\/j.ymthe.2025.12.002_bib11","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1038\/s41571-022-00704-3","article-title":"Overcoming on-target, off-tumour toxicity of CAR T cell therapy for solid tumours","volume":"20","author":"Flugel","year":"2023","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.ymthe.2025.12.002_bib12","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejphar.2021.174516","article-title":"Nectin cell adhesion molecule-4 (NECTIN-4): a potential target for cancer therapy","volume":"911","author":"Chatterjee","year":"2021","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.ymthe.2025.12.002_bib13","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1038\/s41585-020-00394-5","article-title":"The biology and rationale of targeting nectin-4 in urothelial carcinoma","volume":"18","author":"Heath","year":"2021","journal-title":"Nat. Rev. Urol."},{"key":"10.1016\/j.ymthe.2025.12.002_bib14","article-title":"Nectins and Nectin-like Molecules in Colorectal Cancer: Role in Diagnostics, Prognostic Values, and Emerging Treatment Options: A Literature Review","volume":"12","author":"Kobecki","year":"2022","journal-title":"Diagnostics (Basel)"},{"key":"10.1016\/j.ymthe.2025.12.002_bib15","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1309\/AJCPGXK0FR4MHIHB","article-title":"Nectin 4 overexpression in ovarian cancer tissues and serum: potential role as a serum biomarker","volume":"134","author":"DeRycke","year":"2010","journal-title":"Am. J. Clin. Pathol."},{"key":"10.1016\/j.ymthe.2025.12.002_bib16","doi-asserted-by":"crossref","first-page":"3003","DOI":"10.1158\/0008-5472.CAN-15-1313","article-title":"Enfortumab vedotin antibody\u2013drug conjugate targeting nectin-4 is a highly potent therapeutic agent in multiple preclinical cancer models","volume":"76","author":"Challita-Eid","year":"2016","journal-title":"Cancer Res."},{"key":"10.1016\/j.ymthe.2025.12.002_bib17","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1186\/1471-2407-7-73","article-title":"Nectin-4 is a new histological and serological tumor associated marker for breast cancer","volume":"7","author":"Fabre-Lafay","year":"2007","journal-title":"BMC Cancer"},{"key":"10.1016\/j.ymthe.2025.12.002_bib18","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1186\/s12935-019-0824-z","article-title":"Over-expression of Nectin-4 promotes progression of esophageal cancer and correlates with poor prognosis of the patients","volume":"19","author":"Deng","year":"2019","journal-title":"Cancer Cell Int."},{"key":"10.1016\/j.ymthe.2025.12.002_bib19","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1186\/s13046-015-0144-7","article-title":"Nectin-4 expression contributes to tumor proliferation, angiogenesis and patient prognosis in human pancreatic cancer","volume":"34","author":"Nishiwada","year":"2015","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"10.1016\/j.ymthe.2025.12.002_bib20","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1158\/1535-7163.MCT-21-0846","article-title":"The anti-nectin 4: a promising tumor cells target. A systematic review","volume":"21","author":"Bouleftour","year":"2022","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.ymthe.2025.12.002_bib21","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1056\/NEJMoa2035807","article-title":"Enfortumab vedotin in previously treated advanced urothelial carcinoma","volume":"384","author":"Powles","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ymthe.2025.12.002_bib22","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1056\/NEJMoa2312117","article-title":"Enfortumab vedotin and pembrolizumab in untreated advanced urothelial cancer","volume":"390","author":"Powles","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ymthe.2025.12.002_bib23","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1158\/1535-7163.MCT-21-0846","article-title":"The Anti-Nectin 4: A Promising Tumor Cells Target. A Systematic Review","volume":"21","author":"Bouleftour","year":"2022","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.ymthe.2025.12.002_bib24","doi-asserted-by":"crossref","first-page":"157","DOI":"10.54254\/2753-8818\/2024.LA18899","article-title":"On-target off-tumor (OTOT) toxicity from HER2-targeting chimeric antigen receptor (CAR) engineered T cell therapy: current solutions","volume":"74","author":"Ke","year":"2024","journal-title":"Theor. Nat. Sci."},{"key":"10.1016\/j.ymthe.2025.12.002_bib25","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1038\/s41375-020-0734-z","article-title":"B-cell maturation antigen (BCMA) in multiple myeloma: rationale for targeting and current therapeutic approaches","volume":"34","author":"Shah","year":"2020","journal-title":"Leukemia"},{"key":"10.1016\/j.ymthe.2025.12.002_bib26","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.1032403","article-title":"The affinity of antigen-binding domain on the antitumor efficacy of CAR T cells: Moderate is better","volume":"13","author":"Mao","year":"2022","journal-title":"Front. Immunol."},{"key":"10.1016\/j.ymthe.2025.12.002_bib27","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1016\/j.jaad.2024.08.036","article-title":"Dermatologic Toxicities of Antibody-Drug Conjugates","volume":"91","author":"Gronbeck","year":"2024","journal-title":"J. Am. Acad. Dermatol."},{"key":"10.1016\/j.ymthe.2025.12.002_bib28","doi-asserted-by":"crossref","first-page":"8235","DOI":"10.1007\/s00432-023-04761-8","article-title":"TROP-2 is widely expressed in vulvar squamous cell carcinoma and represents a potential new therapeutic target","volume":"149","author":"Condic","year":"2023","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"10.1016\/j.ymthe.2025.12.002_bib29","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1158\/1535-7163.MCT-23-0298","article-title":"An Antibody\u2013Drug Conjugate Directed to Tissue Factor Shows Preclinical Antitumor Activity in Head and Neck Cancer as a Single Agent and in Combination with Chemoradiotherapy","volume":"23","author":"Bakema","year":"2024","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.ymthe.2025.12.002_bib30","doi-asserted-by":"crossref","first-page":"6694","DOI":"10.1158\/0008-5472.CAN-09-0016","article-title":"Identification of nectin-4 oncoprotein as a diagnostic and therapeutic target for lung cancer","volume":"69","author":"Takano","year":"2009","journal-title":"Cancer Res."},{"key":"10.1016\/j.ymthe.2025.12.002_bib31","series-title":"S100A1 and Nectin 4 Biomarkers in Ovarian Cancer","author":"DeRycke","year":"2010"},{"key":"10.1016\/j.ymthe.2025.12.002_bib32","doi-asserted-by":"crossref","first-page":"2291","DOI":"10.1016\/j.ymthe.2025.04.006","article-title":"High-dimensional temporal mapping of CAR T cells reveals phenotypic and functional remodeling during manufacturing","volume":"33","author":"Cadinanos-Garai","year":"2025","journal-title":"Mol. Ther."}],"container-title":["Molecular Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525001625010251?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525001625010251?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,16]],"date-time":"2026-04-16T20:39:48Z","timestamp":1776371988000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1525001625010251"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":32,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["S1525001625010251"],"URL":"https:\/\/doi.org\/10.1016\/j.ymthe.2025.12.002","relation":{},"ISSN":["1525-0016"],"issn-type":[{"value":"1525-0016","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"On-target\/off-tumor toxicities following infusion of low-affinity Nectin-4-specific CAR T cells","name":"articletitle","label":"Article Title"},{"value":"Molecular Therapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ymthe.2025.12.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The American Society of Gene and Cell Therapy. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}